Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 14/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP7 | P09237 | 2/20 | 0.32 |
| ▸ | ADAMTS1 | Q9UHI8 | 2/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714695 | 0.97 | ADAM17 (0.35) | SCN9AADAM17HPGDMMP13FFAR1 | |
| SCHEMBL26874590 | 0.94 | ADAM17 (0.39) | SCN9AADAM17HPGDMMP13ADAMTS4 | |
| SCHEMBL30714700 | 0.93 | ADAM17 (0.33) | SCN9AADAM17HPGDMMP13FFAR1 | |
| SCHEMBL30714666 | 0.90 | ADAM17 (0.34) | ADAM17HPGDMMP13ADAMTS4MMP3 | |
| SCHEMBL31539872 | 0.88 | HPGD (0.32) | ADAM17HPGDADAMTS4MMP3MMP7 | |
| SCHEMBL30714608 | 0.85 | HPGD (0.32) | ADAM17HPGDMMP3 | |
| SCHEMBL30714702 | 0.85 | HPGD (0.33) | ADAM17HPGDADAMTS4MMP3MMP7 | |
| SCHEMBL30714728 | 0.83 | CNR2 (0.34) | ADAM17HPGDMMP13ADAMTS4MMP3 | |
| SCHEMBL30714754 | 0.83 | HPGD (0.32) | ADAM17HPGDMMP3MCHR1 | |
| SCHEMBL30714748 | 0.83 | HTR3A (0.43) | ADAM17MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| CN-119968362-A | Indazole derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-09 | — | — | CN | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | SCN9A 518/4885ADAM17 3090/4885HPGD 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.